Management of Fatty Liver (NAFLD)
The cornerstone of fatty liver management is achieving 7-10% body weight loss through a Mediterranean diet with caloric restriction combined with 150-300 minutes of moderate-intensity exercise weekly, while aggressively treating all cardiovascular risk factors with statins and antihypertensives regardless of traditional thresholds 1, 2.
Immediate Lifestyle Interventions
Weight Loss Strategy
- Target 7-10% body weight reduction to achieve histological improvement in NASH and fibrosis 1
- 5% weight loss improves steatosis alone, but 7-10% is required for meaningful disease modification 1
- Weight loss >10% can achieve NASH resolution and one-stage fibrosis improvement 1
Dietary Approach
- Mediterranean diet is the most evidence-based dietary pattern for NAFLD 1, 3
- Reduce refined carbohydrates and processed foods 1
- Increase vegetables, lean protein, and fish 1
- Refer to formal weight management services when office-based weight loss goals are not achieved 1
Exercise Prescription
- 150-300 minutes of moderate-intensity exercise weekly (or 75-150 minutes vigorous) 2
- Exercise reduces steatosis even without significant weight loss 2
- Aerobic training at 65-75% maximum heart rate is most effective 2
Alcohol Guidance
- Complete abstinence if cirrhosis is present 1
- Minimize or abstain in pre-cirrhotic NAFLD, as alcohol accelerates progression 1
- Reassess alcohol intake at every visit, as consumption fluctuates over time 1
Cardiovascular Risk Management (Critical Priority)
NAFLD patients face 3-fold increased hypertension risk and proatherogenic dyslipidemia. Treat aggressively regardless of liver disease severity:
- Statins are safe and recommended for dyslipidemia management 2
- Control hypertension (target <130/85 mmHg) 1
- Screen annually for diabetes with HbA1c (≥48 mmol/mol or 6.5% is diagnostic) 1
Risk Stratification and Advanced Management
For High-Risk Patients (FIB-4 >2.67 or significant fibrosis)
These patients require hepatologist-coordinated multidisciplinary care 2:
- Vitamin E 800 IU daily for biopsy-proven NASH without diabetes 2
- GLP-1 receptor agonists (liraglutide, semaglutide) improve liver histology and achieve weight loss 2, 4
- Pioglitazone for patients with diabetes and NASH 2, 5
- SGLT2 inhibitors for cardiometabolic benefit in diabetic patients 2
- Consider bariatric surgery in appropriate candidates with obesity and comorbidities 2
Common Pitfalls to Avoid
- Do not restrict statins due to liver disease concerns - they are safe and necessary 2
- Do not wait for symptoms - NAFLD is asymptomatic until advanced stages
- Do not use vitamin E in diabetic patients - evidence is mixed in this population 2
- Do not assume minimal alcohol is safe - even moderate intake accelerates progression 1
Monitoring Strategy
- Quantitative alcohol history at regular intervals 1
- Annual diabetes screening with HbA1c 1
- Regular assessment of blood pressure and lipids 1
- Monitor for cirrhosis complications in high-risk patients 2
The evidence strongly supports that weight loss through diet and exercise remains more effective than any pharmacological intervention for most patients, with medications reserved for high-risk disease or when lifestyle modifications fail 1, 2.